AstraZeneca's Galida Filing Delayed Until 2007 Due To PPAR Safety Concerns

Long-term patient follow-up is extended to two years in light of regulatory concerns about PPAR class safety, firm tells analysts. News is setback for AstraZeneca's near-term cardiovascular pipeline and a boost for Bristol/Merck's muraglitazar.